- KELLY KALSCHEUR
Pediatric and Adult Congenital (PAC) Case Conference will explore congenital heart disease (CHD) along with treatment and management options. Consideration will be given to medical, surgical and non-surgical treatments for patients with Congenital Heart Disease and their overall effect on development, morbidity and mortality. Learners will utilize critical thinking and technical skills to determine optimal care of patients with CHD. Through participation learners will come to better understand barriers to health care that CHD patient's may face.
MDs/DOs, RNs/APRNs, Cardiovascular Techs., and Students
|Luke Lamers, MD, Chair||Kelly Kalscheur, Coordinator|
|Sheri Goar, RN||Cara Miller, CVT|
|In support of improving patient care, the University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.|
Credit Designation Statements
American Medical Association (AMA)
The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Nurses Credentialing Center (ANCC)
The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 1 ANCC contact hour.
ANCC pharmacotherapeutic contact hours will be calculated and awarded as appropriate per session to meet the needs of advanced practice nurses.
Continuing Education Units
The University of Wisconsin–Madison ICEP, as a member of the University Professional & Continuing Education Association (UPCEA), authorizes this program for 0.1 continuing education units (CEUs) or 1 hour.
*Check individual sessions for possible additional credits.
POLICY ON FACULTY AND SPONSOR DISCLOSURE
It is the policy of the University of Wisconsin–Madison Interprofessional Continuing Education Partnership (ICEP) to identify, mitigate and disclose all relevant financial relationships with ineligible companies* held by the speakers/presenters, authors, planners, and other persons who may influence content of this accredited continuing education (CE). In addition, speakers, presenters and authors must disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation. For this accredited continuing education activity, all relevant financial relationships have been mitigated and detailed disclosures are listed below.
* Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.
Detailed disclosures will be available prior to the start of the activity.
Disclosures for Planning Committee
Disclosures for Planning Committee - March 1, 2022 to June 30, 2022
As a result of participation in this education series participants will increase ability to:
- Be be better prepared to use surgical and non-surgical techniques for treating patients with congenital heart disease.
- Make better clinical decisions based on improved understanding of congenital heart anatomy and its effect on a patient's physiology and development.
- Improve communication with other members of the healthcare team providing care to patients with congenital heart disease.
- Plan strategies to decrease disparities in the healthcare system that affect underrepresented groups who require treatment for congenital heart disease.